{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:20:39Z","timestamp":1780374039759,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T00:00:00Z","timestamp":1433980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Postgraduate Research & Innovation Projects of Jiangsu Province","award":["KYZZ_0270"],"award-info":[{"award-number":["KYZZ_0270"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81173174"],"award-info":[{"award-number":["81173174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81202655"],"award-info":[{"award-number":["81202655"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00280-015-2792-x","type":"journal-article","created":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T01:41:36Z","timestamp":1433986896000},"page":"307-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met\/PI3k\/Akt pathway"],"prefix":"10.1007","volume":"76","author":[{"given":"Hongyan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangtian","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunsi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,11]]},"reference":[{"issue":"2","key":"2792_CR1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MAJ.0b013e318246e1b8","volume":"344","author":"S Varughese","year":"2012","unstructured":"Varughese S, Jahangir KS, Simpson CE, Boulmay BC (2012) A paradigm shift in the treatment of advanced non-small cell lung cancer. Am J Med Sci 344(2):147\u2013150. doi: 10.1097\/MAJ.0b013e318246e1b8","journal-title":"Am J Med Sci"},{"issue":"21","key":"2792_CR2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129\u20132139. doi: 10.1056\/NEJMoa040938","journal-title":"N Engl J Med"},{"issue":"5676","key":"2792_CR3","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497\u20131500. doi: 10.1126\/science.1099314","journal-title":"Science"},{"issue":"5","key":"2792_CR4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S1470-2045(12)70117-1","volume":"13","author":"L Zhang","year":"2012","unstructured":"Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M (2012) Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 13(5):466\u2013475. doi: 10.1016\/S1470-2045(12)70117-1","journal-title":"Lancet Oncol"},{"issue":"2","key":"2792_CR5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","volume":"28","author":"D Jackman","year":"2010","unstructured":"Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, Lynch T, Johnson BE, Miller VA (2010) Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28(2):357\u2013360. doi: 10.1200\/JCO.2009.24.7049","journal-title":"J Clin Oncol"},{"issue":"8","key":"2792_CR6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786\u2013792. doi: 10.1056\/NEJMoa044238","journal-title":"N Engl J Med"},{"issue":"5827","key":"2792_CR7","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039\u20131043. doi: 10.1126\/science.1141478","journal-title":"Science"},{"issue":"22","key":"2792_CR8","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","volume":"68","author":"S Yano","year":"2008","unstructured":"Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Sone S (2008) Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68(22):9479\u20139487. doi: 10.1158\/0008-5472.CAN-08-1643","journal-title":"Cancer Res"},{"issue":"12","key":"2792_CR9","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1097\/JTO.0b013e31823ab0dd","volume":"6","author":"S Yano","year":"2011","unstructured":"Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M (2011) Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6(12):2011\u20132017. doi: 10.1097\/JTO.0b013e31823ab0dd","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2792_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","volume":"17","author":"AB Turke","year":"2010","unstructured":"Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Janne PA (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1):77\u201388. doi: 10.1016\/j.ccr.2009.11.022","journal-title":"Cancer Cell"},{"issue":"1","key":"2792_CR11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.tiv.2010.11.001","volume":"25","author":"HF Liao","year":"2011","unstructured":"Liao HF, Chen YJ, Chou CH, Wang FW, Kuo CD (2011) Norcantharidin induces cell cycle arrest and inhibits progression of human leukemic Jurkat T cells through mitogen-activated protein kinase-mediated regulation of interleukin-2 production. Toxicol In Vitro 25(1):206\u2013212. doi: 10.1016\/j.tiv.2010.11.001","journal-title":"Toxicol In Vitro"},{"issue":"4","key":"2792_CR12","first-page":"414","volume":"9","author":"YZ Fan","year":"2010","unstructured":"Fan YZ, Zhao ZM, Fu JY, Chen CQ, Sun W (2010) Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo. Hepatobiliary Pancreat Dis Int 9(4):414\u2013422","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"3","key":"2792_CR13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cbi.2009.07.004","volume":"181","author":"YJ Chen","year":"2009","unstructured":"Chen YJ, Chang WM, Liu YW, Lee CY, Jang YH, Kuo CD, Liao HF (2009) A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. Chem Biol Interact 181(3):440\u2013446. doi: 10.1016\/j.cbi.2009.07.004","journal-title":"Chem Biol Interact"},{"issue":"12","key":"2792_CR14","doi-asserted-by":"crossref","first-page":"e84610","DOI":"10.1371\/journal.pone.0084610","volume":"8","author":"B Shen","year":"2013","unstructured":"Shen B, He PJ, Shao CL (2013) Norcantharidin induced DU145 cell apoptosis through ROS-mediated mitochondrial dysfunction and energy depletion. PLoS One 8(12):e84610. doi: 10.1371\/journal.pone.0084610","journal-title":"PLoS One"},{"key":"2792_CR15","first-page":"461487","volume":"2013","author":"H Lv","year":"2013","unstructured":"Lv H, Li Y, Du H, Fang J, Song X, Zhang J (2013) The synthetic compound norcantharidin induced apoptosis in mantle cell lymphoma in vivo and in vitro through the PI3K-Akt-NF- kappa B signaling pathway. Evid Based Complement Alter Med 2013:461487. doi: 10.1155\/2013\/461487","journal-title":"Evid Based Complement Alter Med"},{"issue":"9","key":"2792_CR16","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.cellsig.2012.05.009","volume":"24","author":"S Zhang","year":"2012","unstructured":"Zhang S, Li G, Ma X, Wang Y, Liu G, Feng L, Zhao Y, Zhang G, Wu Y, Ye X, Qin B, Lu J (2012) Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal 24(9):1803\u20131809. doi: 10.1016\/j.cellsig.2012.05.009","journal-title":"Cell Signal"},{"issue":"6","key":"2792_CR17","first-page":"953","volume":"31A","author":"XH Liu","year":"1995","unstructured":"Liu XH, Blazsek I, Comisso M, Legras S, Marion S, Quittet P, Anjo A, Wang GS, Misset JL (1995) Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur J Cancer 31A(6):953\u2013963","journal-title":"Eur J Cancer"},{"issue":"1","key":"2792_CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3892\/or.2012.2118","volume":"29","author":"YC Lee","year":"2013","unstructured":"Lee YC, Lee LM, Yang CH, Lin AM, Huang YC, Hsu CC, Chen MS, Chi CW, Yin PH, Kuo CD, Liao JF, Lee HC (2013) Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells. Oncol Rep 29(1):237\u2013243. doi: 10.3892\/or.2012.2118","journal-title":"Oncol Rep"},{"issue":"8","key":"2792_CR19","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/1078-0432.CCR-10-1993","volume":"17","author":"IS Donev","year":"2011","unstructured":"Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S (2011) Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 17(8):2260\u20132269. doi: 10.1158\/1078-0432.CCR-10-1993","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2792_CR20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0022-1759(84)90190-X","volume":"70","author":"LM Green","year":"1984","unstructured":"Green LM, Reade JL, Ware CF (1984) Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods 70(2):257\u2013268","journal-title":"J Immunol Methods"},{"issue":"21","key":"2792_CR21","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1158\/1078-0432.CCR-09-1001","volume":"15","author":"W Wang","year":"2009","unstructured":"Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S (2009) Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 15(21):6630\u20136638. doi: 10.1158\/1078-0432.CCR-09-1001","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2792_CR22","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1158\/0008-5472.CAN-06-3339","volume":"67","author":"T Okabe","year":"2007","unstructured":"Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, Takada M, Fukuoka M, Nakagawa K (2007) Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 67(5):2046\u20132053. doi: 10.1158\/0008-5472.CAN-06-3339","journal-title":"Cancer Res"},{"issue":"6","key":"2792_CR23","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-11-1171","volume":"18","author":"W Wang","year":"2012","unstructured":"Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S (2012) Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res 18(6):1663\u20131671. doi: 10.1158\/1078-0432.CCR-11-1171","journal-title":"Clin Cancer Res"},{"issue":"33","key":"2792_CR24","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1038\/onc.2012.396","volume":"32","author":"S Gusenbauer","year":"2013","unstructured":"Gusenbauer S, Vlaicu P, Ullrich A (2013) HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 32(33):3846\u20133856. doi: 10.1038\/onc.2012.396","journal-title":"Oncogene"},{"issue":"10","key":"2792_CR25","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","volume":"361","author":"R Rosell","year":"2009","unstructured":"Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958\u2013967. doi: 10.1056\/NEJMoa0904554","journal-title":"N Engl J Med"},{"issue":"27","key":"2792_CR26","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1200\/JCO.2012.46.1764","volume":"31","author":"JC Yang","year":"2013","unstructured":"Yang JC, Hirsh V, Schuler M, Yamamoto N, O\u2019Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV (2013) Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin\/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3342\u20133350. doi: 10.1200\/JCO.2012.46.1764","journal-title":"J Clin Oncol"},{"issue":"2","key":"2792_CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121\u2013128. doi: 10.1016\/S1470-2045(09)70364-X","journal-title":"Lancet Oncol"},{"issue":"8","key":"2792_CR28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, You C (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735\u2013742. doi: 10.1016\/S1470-2045(11)70184-X","journal-title":"Lancet Oncol"},{"issue":"3","key":"2792_CR29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239\u2013246. doi: 10.1016\/S1470-2045(11)70393-X","journal-title":"Lancet Oncol"},{"issue":"4","key":"2792_CR30","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3390\/cancers2042153","volume":"2","author":"LP Stabile","year":"2010","unstructured":"Stabile LP, Rothstein ME, Keohavong P, Lenzner D, Land SR, Gaither-Davis AL, Kim KJ, Kaminski N, Siegfried JM (2010) Targeting of both the c-Met and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic mice. Cancers (Basel) 2(4):2153\u20132170. doi: 10.3390\/cancers2042153","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2792_CR31","first-page":"433","volume":"57","author":"JM Siegfried","year":"1997","unstructured":"Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, Landreneau RJ (1997) Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 57(3):433\u2013439","journal-title":"Cancer Res"},{"issue":"12","key":"2792_CR32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/gcc.20604","volume":"47","author":"PC Ma","year":"2008","unstructured":"Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R (2008) Expression and mutational analysis of MET in human solid cancers. Genes Chromosom Cancer 47(12):1025\u20131037. doi: 10.1002\/gcc.20604","journal-title":"Genes Chromosom Cancer"},{"key":"2792_CR33","first-page":"243859","volume":"2013","author":"XH Kang","year":"2013","unstructured":"Kang XH, Xu ZY, Gong YB, Wang LF, Wang ZQ, Xu L, Cao F, Liao MJ (2013) Bufalin reverses HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via blockage of Met\/PI3k\/Akt pathway and induction of apoptosis. Evid Based Complement Alter Med 2013:243859. doi: 10.1155\/2013\/243859","journal-title":"Evid Based Complement Alter Med"},{"issue":"5","key":"2792_CR34","doi-asserted-by":"crossref","first-page":"e37006","DOI":"10.1371\/journal.pone.0037006","volume":"7","author":"YJ Chen","year":"2012","unstructured":"Chen YJ, Kuo CD, Chen SH, Chen WJ, Huang WC, Chao KS, Liao HF (2012) Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells. PLoS One 7(5):e37006. doi: 10.1371\/journal.pone.0037006","journal-title":"PLoS One"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2792-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2792-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2792-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T12:17:22Z","timestamp":1566821842000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2792-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,11]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["2792"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2792-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,11]]}}}